Synergistic Breast Cancer Treatment System

Publication ID: 24-11857639_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Breast Cancer Treatment System,” Published Technical Disclosure No. 24-11857639_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857639_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,639.

Summary of the Inventive Concept

A comprehensive breast cancer treatment system integrating nanomedicinal compositions with AI, IoT, blockchain, and advanced materials to provide personalized, efficient, and secure treatment planning and delivery.

Background and Problem Solved

The original patent disclosed a nanomedicinal composition for treating breast cancer, but it had limitations in terms of personalized treatment planning, secure data management, and real-time feedback. The new inventive concept addresses these limitations by integrating the nanomedicinal composition with advanced technologies to create a more powerful and efficient system.

Detailed Description of the Inventive Concept

The synergistic breast cancer treatment system comprises a nanomedicinal composition with a nanocarrier and a pharmaceutical agent mixture, integrated with an AI-powered diagnostic module for personalized treatment planning. The system also includes a blockchain-based data management system for secure patient data storage and IoT-enabled sensors for real-time feedback. Additionally, the nanocarrier can be functionalized with graphene-based materials for enhanced biocompatibility and targeted delivery. The system can be further combined with microfluidic devices for point-of-care diagnostics and cloud-based analytics platforms for data analysis and treatment outcome prediction.

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, blockchain, and advanced materials with the original nanomedicinal composition, providing a novel and non-obvious solution for personalized and efficient breast cancer treatment. The inventive step lies in the synergistic combination of these technologies to create a more powerful system.

Alternative Embodiments and Variations

Alternative embodiments of the system could include the use of different AI algorithms, various types of IoT sensors, or alternative blockchain platforms. The system could also be adapted for treating other types of cancer or diseases, or integrated with other diagnostic tools and devices.

Potential Commercial Applications and Market

The synergistic breast cancer treatment system has significant commercial potential in the healthcare industry, particularly in the areas of personalized medicine and cancer treatment. The system could be marketed to hospitals, research institutions, and pharmaceutical companies, and could potentially disrupt the current breast cancer treatment landscape.

CPC Classifications

Section	Class	Group
A	A61	A61K47/6923
A	A61	A61K31/138
A	A61	A61K31/282
A	A61	A61K33/243
A	A61	A61K47/10
A	A61	A61K2121/00
A	A61	A61K2800/47
B	B82	B82Y5/00
B	B82	B82Y25/00
B	B82	B82Y30/00
B	B82	B82Y40/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Nanomedicine, cancer therapeutics, and biomedical engineering, with expertise in nanocarrier design, drug delivery systems, and advanced medical technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher or engineer with advanced degrees in materials science, biomedical engineering, or pharmaceutical sciences, possessing knowledge of nanoparticle fabrication, cancer treatment strategies, and emerging medical technologies

Obviousness Rationale

A person of ordinary skill would recognize that integrating digital technologies with nanomedicinal compositions represents a predictable extension of existing cancer treatment methodologies. The combination of AI, IoT, and blockchain with established nanocarrier technologies provides a logical progression in personalized medicine approaches. The technical elements introduced in the PTD represent incremental improvements that would be apparent to a skilled practitioner seeking to enhance treatment efficacy and patient monitoring.

Obvious Combinations & Variations

Source Patent Element

Nanocarrier with mesosilicalite and magnetic ferrite particles for breast cancer treatment

PTD Variation

Adding AI-powered diagnostic module for personalized treatment planning

Obviousness Reasoning

Integrating computational analysis with drug delivery is a known technique in precision medicine, representing a predictable application of machine learning to existing nanomedicinal approaches

Source Patent Element

Pharmaceutical composition with anti-cancer therapeutic

PTD Variation

Incorporating IoT-enabled sensors for real-time treatment monitoring

Obviousness Reasoning

Continuous patient monitoring is a standard approach in medical treatment, and applying sensor technologies to nanomedicine represents an obvious design choice for improving treatment outcomes

Source Patent Element

Nanocarrier with porous silicate matrix

PTD Variation

Functionalization with graphene-based materials for enhanced biocompatibility

Obviousness Reasoning

Material surface modification is a well-established technique in nanomedicine, and graphene's known biocompatibility makes its application a predictable improvement to existing nanocarrier designs

Source Patent Element

Breast cancer treatment method using nanomedicinal composition

PTD Variation

Blockchain-based data management for secure patient information tracking

Obviousness Reasoning

Secure data management is a critical concern in medical technologies, and blockchain represents a known solution for addressing data security and patient privacy challenges

Source Patent Element

Pharmaceutical composition with anti-cancer therapeutic

PTD Variation

Microfluidic device integration for point-of-care diagnostics

Obviousness Reasoning

Miniaturization and point-of-care diagnostic technologies are well-established trends in medical device development, representing an obvious approach to improving treatment accessibility

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857639 and the disclosed variations, a person of ordinary skill in the art would find the claimed innovations obvious and anticipated. The incremental technological additions represent predictable combinations of known techniques in nanomedicine and digital health technologies, thereby rendering subsequent claims obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,639
Title	Method for treating breast cancer
Assignee(s)	Imam Abdulrahman Bin Faisal University